Skip to main content
Ulisse Biomed logo

Ulisse Biomed — Investor Relations & Filings

Ticker · UBM ISIN · IT0005451213 LEI · 815600F9C180B297BE35 XMIL Professional, scientific and technical activities
Open in API
Filings indexed 134 across all filing types
Latest filing 2025-03-12 Regulatory Filings
Country IT Italy
Listing XMIL UBM

About Ulisse Biomed

https://www.ulissebiomed.com/

Ulisse Biomed is a healthcare biotechnology company specializing in distributed and connected diagnostic solutions. The company develops an integrated platform that includes miniaturized qPCR instruments, an AI-driven cloud-based software, and advanced multiplexing reagents. This technology enables genetic testing for a wide range of users, from large clinical and diagnostic laboratories to smaller, peripheral labs in industrial settings. Its primary markets are healthcare and diagnostics, serving hospitals and clinics, and the agrifood and nutraceutical sectors. The company also provides OEM and development services. In late 2025, shareholders approved a proposal to change the corporate name to Helyx Industries S.p.A.

Recent filings

Filing Released Lang Actions
AVVIO DELLA SECONDA FASE DEL PROGETTO DI SVILUPPO PER LA LOTTA CONTRO LA MALARIA
Regulatory Filings Classification · 1% confidence The document is titled 'AVVIO DELLA SECONDA FASE DEL PROGETTO DI SVILUPPO PER LA LOTTA CONTRO LA MALARIA' (Start of the Second Phase of the Development Project for the Fight Against Malaria). It is an official communication ('Informazione Regolamentata') released on March 12, 2025, by Ulisse Biomed S.p.A. The content details the continuation of a project funded by the Gates Foundation, referencing a previous announcement from February 20, 2024. This structure—announcing the start or continuation of a specific corporate/research activity, often referencing prior regulatory steps—is characteristic of a general regulatory announcement that doesn't fit the specific financial report categories (like 10-K, ER, IR) or specific corporate actions (like DIV, SHA, DIRS). Since it is a formal, non-financial-statement announcement of a significant operational/research milestone, and it is not a proxy statement (DEF 14A), director dealing (DIRS), or capital change (CAP), the most appropriate general category for a regulatory update that doesn't fit elsewhere is Regulatory Filings (RNS). It is not an Earnings Release (ER) or Interim Report (IR) as it focuses on project development, not period financial results.
2025-03-12 Italian
COMUNICAZIONE DI VARIAZIONE DEL CAPITALE SOCIALE
Share Issue/Capital Change Classification · 1% confidence The document is an official communication from Ulisse Biomed S.p.A. titled "COMUNICAZIONE DI VARIAZIONE DEL CAPITALE SOCIALE" (Communication of Change in Share Capital). It details the results of a capital increase (both paid and free) and presents the resulting new composition of the subscribed and paid-in share capital, including shareholder participation percentages. This directly relates to changes in the company's capital structure and share issuance. This aligns perfectly with the definition of 'Share Issue/Capital Change' (Code: SHA). It is not a general earnings release (ER), an annual report (10-K), or a simple announcement of a report (RPA), as it contains the substantive details of the capital change itself.
2025-02-14 Italian
CALENDARIO EVENTI SOCIETARI 2025
Report Publication Announcement Classification · 1% confidence The document is titled 'CALENDARIO EVENTI SOCIETARI 2025' (Corporate Events Calendar 2025) and explicitly states that the company is making known the calendar of corporate events for the year 2025, pursuant to Article 17 of the Euronext Growth Milan Issuers Regulation. This document is an announcement detailing future dates for board meetings (approving financial statements) and shareholder meetings. It is not the financial report itself (like 10-K or IR), nor is it a transcript or a presentation. Since it is an official announcement regarding the schedule of corporate activities and regulatory deadlines, it fits best under the general category of Regulatory Filings (RNS), as it is a formal disclosure to the market about future scheduled events, which doesn't fit the more specific categories like DIV, ER, or AGM-R (which would be materials *from* the AGM). Given the nature of providing a schedule of future regulatory/corporate actions, RNS is the most appropriate general regulatory disclosure category.
2025-01-29 Italian
COMUNICAZIONE CAMBIAMENTO SOSTANZIALE DEGLI AZIONISTI RILEVANTI (ART.17 REGOLAMENTO EMITTENTI EGM)
Major Shareholding Notification Classification · 1% confidence The document is an official communication ('COMUNICAZIONE CAMBIAMENTO SOSTANZIALE DEGLI AZIONISTI RILEVANTI') issued by Ulisse Biomed S.p.A. on December 30, 2024, pursuant to Article 17 of the Euronext Growth Milan Issuers Regulation. The core content details changes in significant shareholder holdings following a capital increase subscription, explicitly listing updated share percentages for various shareholders. This type of filing, which reports changes in ownership above certain thresholds (like the 5% mentioned), directly corresponds to the definition of a Major Shareholding Notification. The code for this is MRQ.
2024-12-30 Italian
INTERAMENTE SOTTOSCRITTO L’AUMENTO DI CAPITALE SOCIALE PER UN AMMONTARE COMPLESSIVO DI EURO 1.309.000
Capital/Financing Update Classification · 1% confidence The document is an official regulatory announcement (Informazione Regolamentata) from Ulisse Biomed S.p.A. The subject ('Oggetto') explicitly states: 'INTERAMENTE SOTTOSCRITTO L'AUMENTO DI CAPITALE SOCIALE PER UN AMMONTARE COMPLESSIVO DI EURO 1.309.000' (Capital Increase fully subscribed for a total amount of Euro 1,309,000). The text details the issuance of new ordinary shares, exclusion of pre-emptive rights, and the subscription by a strategic partner (Algebris). This content directly relates to fundraising, financing activities, and changes in the capital structure. Therefore, the most appropriate classification is Capital/Financing Update (CAP). It is not a general earnings release (ER) or a comprehensive quarterly report (IR), but a specific announcement about a capital transaction.
2024-12-30 Italian
IL CONSIGLIO DI AMMINISTRAZIONE ESERCITA LA DELEGA AD AUMENTARE IL CAPITALE SOCIALE
Capital/Financing Update Classification · 1% confidence The document is an official press release (Informazione Regolamentata) from Ulisse Biomed S.p.A. dated December 27, 2024. The subject ('Oggetto') explicitly states that the Board of Directors is exercising its delegation to increase the share capital ('ESERCITA LA DELEGA AD AUMENTARE IL CAPITALE SOCIALE'). The text details the issuance of 1,700,000 new ordinary shares at a price of EUR 0.77 per share, excluding pre-emptive rights, to a strategic institutional investor. This action directly relates to fundraising, financing activities, and changes in the capital structure. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it involves shares, it is an announcement of a capital increase execution, not a general share repurchase (POS) or a general share issue announcement (SHA), but specifically a financing event.
2024-12-27 Italian

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.